IRL757

PreclinicalSmall molecule

IIntegrative Research Laboratories AB

IRL757 is one of 2 small molecule programs targeting PARKINSON DISEASE (Disorder). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PARKINSON DISEASE (disorder)Recruiting

PARKINSON DISEASE (disorder)Preclinical

Recruiting

Competition

Competitive Landscape

2 competitors in PARKINSON DISEASE (disorder)

#DrugCompanyPhaseTrials

AB-1005

AAskBio Inc

Phase 2

1 2

IRL757

IIntegrative Research Laboratories AB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

PARKINSON DISEASE (disorder)

NCT07461220

Clinical

Trials by Indication[1]

Trial1 trial

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Completed·IIntegrative Research Laboratories AB·Phase 1·NCT06493045·82 enrolled

Elderly1 trial

Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers

Completed·IIntegrative Research Laboratories AB·Phase 1·NCT06699628·12 enrolled

PARKINSON DISEASE (Disorder)1 trial

A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants With Parkinson's Disease and Apathy

Recruiting·IIntegrative Research Laboratories AB·Preclinical·NCT07461220·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IRL757. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IRL757 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IRL757. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Integrative Research Laboratories AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIntegrative Research Laboratories AB

IRL757

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Trial1 trial

Elderly1 trial

PARKINSON DISEASE (Disorder)1 trial

References

Drug Info

Quick Facts

Related News